Abstract:Abstract Background The discovery of the importance of angiogenesis in tumor growth has emphasized the need to find specific vascular targets for tumor-targeted therapies. Previously, using phage display technology, we identified the peptide GX1 as having the ability to target the gastric cancer vasculature. The present study investigated the bioactivities of GX1, as well as its potential ability to cooperate with recombinant mutant human tumor necrosis factor alpha (rmhTNFα), in gastric cancer therapy. Results Tetrazolium salt (MTT) assay showed that GX1 could inhibit cell proliferation of both human umbilical vein endothelial cells (HUVEC) (44%) and HUVEC with tumor endothelium characteristics, generated by culturing in tumor-conditioned medium (co-HUVEC) (62%). Flow-cytometry (FCM) and western blot assays showed that GX1 increased the rate of apoptosis from 11% to 31% (p < 0.01) by up-regulating caspase 3 expression level. A chorioallantoic membrane assay indicated that GX1 could suppress neovascularization in vivo, with the microvessel count decreasing from 21 to 11 (p < 0.05). When GX1 was fused to rmhTNFα, GX1-rmhTNFα selectively concentrated in the gastric cancer vasculature, as shown by enzyme-linked immunosorbent assay, immunofluorescence and emission-computed tomography. In vitro MTT and FCM assays showed that, compared to rmhTNFα alone, GX1-rmhTNFα was more effective at suppressing co-HUVEC proliferation (45% vs. 61%, p < 0.05) and inducing apoptosis (11% vs. 23%, p < 0.05). In a tumor formation test, GX1-rmhTNFα more effectively inhibited tumor growth than rmhTNFα (tumor volume: 271 mm3 vs. 134 mm3, p < 0.05), with less systemic toxicity as measured by body weight (20.57 g vs. 19.30 g, p < 0.05). These therapeutic effects may be mediated by selectively enhanced tumor vascular permeability, as indicated by Evan's blue assay. Conclusion GX1 had both homing activity and the ability to inhibit vascular endothelial cell proliferation in vitro and neovascularization in vivo. Furthermore, when GX1 was conjugated to rmhTNFα, the fusion protein was selectively delivered to targeted tumor sites, significantly improving the anti-tumor activity of rmhTNFα and decreasing systemic toxicity. These results demonstrate the potential of GX1 as a homing peptide in vascular targeted therapy for gastric cancer.

ANXA1‑derived Peptides Suppress Gastric and Colon Cancer Cell Growth by Targeting EphA2 Degradation.

ANXA1 Drives Nasopharyngeal Carcinoma Growth and Metastasis by Binding and Stabilizing EphA2 and the Anti-Tumor Effect of ANXA1-Derived Peptide

ANXA1 Binds and Stabilizes EphA2 to Promote Nasopharyngeal Carcinoma Growth and Metastasis

ANXA1 derived polypeptide and application thereof

Expression and Significance of Annexin A2 in Patients with Gastric Adenocarcinoma and the Association with E-cadherin.

Supplementary Data from ANXA1 Binds and Stabilizes EphA2 to Promote Nasopharyngeal Carcinoma Growth and Metastasis

EphA2–YES1–ANXA2 Pathway Promotes Gastric Cancer Progression and Metastasis

A therapeutic antibody targeting annexin-A1 inhibits cancer cell growth in vitro and in vivo

ANXA2 regulates the behavior of SGC-7901 cells.

Abstract B201: Selective Peptides for Targeting EphA2 in Cancer Cells

ANXA2 Silencing Inhibits Proliferation, Invasion, and Migration in Gastric Cancer Cells

Effect of Annexin A1 gene on the proliferation and invasion of esophageal squamous cell carcinoma cells and its regulatory mechanisms

Annexin A1 is associated with gastric cancer survival and promotes gastric cancer cell invasiveness through the formyl peptide receptor/extracellular signal-regulated kinase/integrin beta-1-binding protein 1 pathway

Geldanamycin Mediates the Apoptosis of Gastric Carcinoma Cells Through Inhibition of EphA2 Protein Expression.

Annexin A2 Enhances the Progression of Colorectal Cancer and Hepatocarcinoma via Cytoskeleton Structural Rearrangements

Annexin A2 is Implicated in Multi-Drug-resistance in Gastric Cancer Through P38mapk and AKT Pathway.

Differential Expression of ANXA1 in Benign Human Gastrointestinal Tissues and Cancers

Anti-tumour effects of small interfering RNA targeting anion exchanger 1 in experimental gastric cancer.

Novel Peptide GX1 Inhibits Angiogenesis by Specifically Binding to Transglutaminase-2 in the Tumorous Endothelial Cells of Gastric Cancer

A Novel Peptide (GX1) Homing to Gastric Cancer Vasculature Inhibits Angiogenesis and Cooperates with TNF Alpha in Anti-Tumor Therapy

Targeting ANXA1 Abrogates Treg-mediated Immune Suppression in Triple-Negative Breast Cancer